Saturday 17 October 2026
Export TRDA’s income statement to Excel — free account
Entrada Therapeutics, Inc.
TRDA Healthcare Biotechnology
Entrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024. In the quarter to June 2026, revenue fell 54.0%, EPS grew 2.88% and free cash flow fell 9.10%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.36
0.42
−8.79%
Follow TRDA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 8.69 | 0.00 | — | — | — | — | — |
Altman Z-Score |
2.15 | 5.23 | 1.53 | — | — | — | — | — |
P/S ratio |
16.73 | 3.06 | 3.89 | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 3.74 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
4.24 | 9.40 | 2.67 | — | — | — | — | — |
P/Operating CF |
(13.21) | (20.41) | (124.94) | — | — | — | — | — |
Beneish M-Score |
(6.07) | (1.32) | — | — | — | — | — | — |
P/B ratio |
1.39 | 1.50 | 2.07 | — | — | — | — | — |
Price to Tangible BV |
1.39 | 1.50 | 2.07 | — | — | — | — | — |
EV/Sales |
5.07 | 1.07 | 1.16 | — | — | — | — | — |
EV/EBITDA |
0.00 | 5.52 | 0.00 | — | — | — | — | — |
EV/Operating CF |
(1.00) | (5.41) | 1.07 | — | — | — | — | — |
EV/FCF |
(1.00) | (5.03) | 1.11 | — | — | — | — | — |
Quick Ratio |
12.17 | 10.73 | 2.25 | 8.59 | 43.32 | 11.62 | 8.77 | — |
Current Ratio |
12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 | — |
Net Debt/EBITDA |
1.88 | (10.30) | 57.70 | 1.98 | 5.82 | 1.48 | 1.44 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.06 | 0.42 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.89 | (0.63) | (20.91) | 0.99 | 0.99 | 0.96 | 2.12 | — |
Capex/Depreciation |
(2.45) | 0.51 | 1.91 | (1.41) | (4.10) | (7.11) | (6.06) | — |
| (39.13%) | 19.56% | (2.94%) | (37.01%) | (39.78%) | 93.05% | 17.89% | — | |
| (31.81%) | 13.18% | (1.85%) | (33.92%) | (29.29%) | (85.88%) | (55.93%) | — | |
ROIC |
(1,009.37%) | 338.50% | 0.00% | (254.93%) | (417.49%) | (1,484.14%) | 0.00% | — |
Return on Tangible Assets |
(49.72%) | 15.95% | (3.01%) | (48.38%) | (17.15%) | (66.93%) | (31.26%) | — |
Average Days of Receivables |
16.90 | 6.37 | 16.63 | — | — | — | — | — |
Research and Development Expense of Revenue |
559.65% | 59.45% | 77.42% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
161.48% | 18.25% | 25.03% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
77.14% | 8.50% | 10.16% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.55 | 0.53 | 0.29 | — | — | — | — | — |
Graham Number |
0.00 | 22.68 | 0.00 | — | — | — | — | — |
Earnings Yield |
(33.66%) | 11.51% | (1.38%) | — | — | — | — | — |
Free Cash Flow Yield |
(30.46%) | (6.93%) | 26.76% | — | — | — | — | — |
Revenue per Share |
0.61 | 5.65 | 3.90 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(3.11) | (1.11) | 4.23 | (3.00) | (8.11) | (23.13) | (11.58) | — |
Capex per Share |
(0.03) | (0.08) | (0.17) | (0.09) | (0.73) | (2.10) | (0.68) | — |
Free Cash Flow per Share |
(3.13) | (1.20) | 4.06 | (3.09) | (8.85) | (25.23) | (12.25) | — |
Cash per Share |
7.16 | 11.26 | 10.65 | 6.03 | 46.44 | 35.33 | 18.05 | — |
Shareholders Equity per Share |
7.40 | 11.49 | 7.33 | 6.79 | 47.66 | 36.34 | 17.47 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
7.40 | 11.49 | 7.33 | 6.79 | 47.66 | 36.34 | 17.47 | — |
Free Cash Flow |
(129.55) | (44.71) | 134.19 | (96.67) | (55.44) | (27.89) | (11.43) | — |
Working Capital |
281.80 | 400.56 | 210.98 | 187.90 | 291.98 | 36.59 | 15.52 | — |
Capital Expenditures |
(1.04) | (3.16) | (5.61) | (2.89) | (4.58) | (2.32) | (0.63) | — |
Net Current Asset Value |
235.01 | 342.40 | 142.94 | 170.37 | 291.59 | 36.59 | 15.50 | — |
EV/EBIT |
0.00 | 4.79 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.04 | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 13.72 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.06 | (0.57) | (0.26) | 0.27 | 0.18 | 0.11 | 0.13 | — |
Cash ROIC |
(21.50%) | (5.27%) | 22.58% | (24.09%) | (9.40%) | (35.21%) | (34.49%) | — |
Accounts Receivable Turnover |
10.47 | 44.11 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
2.43 | 4.78 | — | — | — | — | — | — |
Average Payables |
3.27 | 3.77 | 4.63 | 3.35 | 1.15 | 1.16 | 1.16 | — |
Average Assets |
451.85 | 497.76 | 360.62 | 278.94 | 174.68 | 30.88 | 9.12 | — |
Average Common Equity |
367.41 | 335.52 | 227.46 | 255.64 | 128.61 | (28.50) | (28.50) | — |
Columns are period end dates